<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01701583</url>
  </required_header>
  <id_info>
    <org_study_id>12-0780</org_study_id>
    <nct_id>NCT01701583</nct_id>
  </id_info>
  <brief_title>Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria</brief_title>
  <official_title>Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at changes in cell proteins in people with chronic hives treated with
      omalizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate for changes in the proteins produced in white blood
      cells (basophils) in patients with chronic hives who are treated with and respond to
      omalizumab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the basophil proteome</measure>
    <time_frame>Baseline through week 13</time_frame>
    <description>In patients with chronic urticaria who respond clinically to omalizumab, the proteome of blood basophils will be measured at baseline (pre-treatment) and at weeks 6 and 13 (post-treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in basophil proteome in responders to omalizumab compared to non-responders to omalizumab</measure>
    <time_frame>Baseline through week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.</description>
    <arm_group_label>Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic urticaria (hives) for more than 6 weeks.

          -  No improvement with standard doses of antihistamines (loratadine 10 mg daily,
             desloratadine 5 mg daily, fexofenadine 180 mg daily, cetirizine 10 mg daily, or
             levocetirizine 5 mg daily)

        Exclusion Criteria:

          -  Taken any oral steroids for 1 month prior to beginning the study.

          -  Taken any other immunomodulatory drugs (sulfasalazine, hydroxychloroquine,
             cyclosporine, methotrexate) for 1 month prior to beginning the study.

          -  Physical urticaria as a primary diagnosis.

          -  Known allergic precipitant of urticaria such as foods.

          -  Urticarial Vasculitis.

          -  Anemia.

          -  Asthma.

          -  Serum Immunoglobulin E (IgE) &gt;700 IU/ml.

          -  Women of childbearing potential not using contraception method(s), as well as women
             who are pregnant and/or breastfeeding.

          -  Known sensitivity to omalizumab or this class of drug.

          -  Use of any other investigational agent in the last 1 month.

          -  Untreated intercurrent illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Dreskin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2012</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Idiopathic Urticaria</keyword>
  <keyword>CIU</keyword>
  <keyword>Urticaria</keyword>
  <keyword>Chronic Hives</keyword>
  <keyword>Xolair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

